View Older Stories View More Recent Stories

Mar 30, 2026 08:05AM Esperion presents stroke reduction data for NEXLETOL at cardiology conference
Mar 16, 2026 05:40PM BofA maintains Underperform on Esperion Therapeutics (ESPR) despite favorable new AHA/ACC guidelines
Mar 16, 2026 06:31AM Esperion's bempedoic acid gets class 1 recommendations in new guidelines
Mar 13, 2026 05:40AM Esperion Therapeutics (ESPR) PT Raised to $5 at Citizens After Q4 Results
Mar 10, 2026 12:17PM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR): "we expect continued growth"
Mar 10, 2026 06:52AM Esperion Therapeutics (ESPR) Misses Q4 EPS by 7c ; Provides Outlook
Feb 17, 2026 08:00AM Esperion settles with fifth generic drug maker over cholesterol patents
Dec 22, 2025 07:06AM Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
Nov 25, 2025 12:48AM Piper Sandler Starts Esperion Therapeutics (ESPR) at Overweight
Nov 21, 2025 08:01AM Otsuka launches NEXLETOL in Japan, triggering $90 million payment to Esperion
Nov 18, 2025 07:02AM NILEMDO receives Health Canada approval for LDL cholesterol reduction
Nov 12, 2025 07:02AM Esperion Therapeutics' (ESPR) Portfolio Not Fully Priced In - Cantor Fitzgerald
Nov 12, 2025 04:57AM Esperion Therapeutics' (ESPR) LDL-Lowering Drug Supported by KOLs - Citizens
Nov 6, 2025 06:31AM Esperion Therapeutics (ESPR) Misses Q3 EPS by 18c
Oct 17, 2025 07:12AM Cantor Fitzgerald Reiterates Overweight Rating on Esperion Therapeutics (ESPR): Says Expenses Manageable
Oct 17, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)
Oct 6, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)
Oct 3, 2025 08:00AM Esperion settles patent dispute with Dr. Reddy's over generic drugs
Sep 22, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)
Sep 22, 2025 04:24AM Citizens JMP Reiterates Market Outperform Rating on Esperion Therapeutics (ESPR)
Sep 19, 2025 08:02AM Otsuka receives approval to market NEXLETOL in Japan for cholesterol
Aug 11, 2025 04:13PM Esperion delays Q2 quarterly report filing due to financial close issues
Aug 5, 2025 06:19AM Esperion Therapeutics (ESPR) Tops Q2 EPS by 12c
Jul 24, 2025 12:48PM Esperion Therapeutics (ESPR) on watch on vague chatter
Jul 8, 2025 08:01AM Esperion (ESPR) settles with Accord Healthcare over NEXLETOL generic
Jul 1, 2025 08:07AM Esperion Therapeutics (ESPR) Appoints Craig Thompson to its Board
Jun 17, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)
Jun 13, 2025 07:18AM Cantor Fitzgerald Reiterates Overweight Rating on Esperion Therapeutics (ESPR)
Jun 2, 2025 08:03AM Esperion Therapeutics (ESPR) Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL
May 12, 2025 08:03AM Esperion Therapeutics (ESPR) Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL Prior to April 19, 2040
May 8, 2025 06:30AM Esperion Therapeutics (ESPR) Partners with HLS Therapeutics to Commercialize NEXLETOL and NEXLIZET in Canada
May 6, 2025 06:37AM Esperion Therapeutics (ESPR) Misses Q1 EPS by 5c
Apr 25, 2025 06:56AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)
Apr 24, 2025 08:03AM Esperion Therapeutics (ESPR) Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
Apr 1, 2025 08:03AM Esperion Therapeutics (ESPR) Appoints Robert E. Hoffman to its Board
Mar 24, 2025 05:45AM Citizens JMP Reiterates Market Outperform Rating on Esperion Therapeutics (ESPR)
Mar 20, 2025 08:00AM Esperion Therapeutics (ESPR) Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid
Mar 5, 2025 05:28AM Citizens JMP Reiterates Market Outperform Rating on Esperion Therapeutics (ESPR)
Mar 4, 2025 06:09AM Esperion Therapeutics (ESPR) Tops Q4 EPS by 3c
Mar 3, 2025 08:01AM Esperion Therapeutics (ESPR) Partners with CSL Seqirus to Commercialize NEXLETOL and NEXLIZET in Australia
Feb 11, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)
Feb 11, 2025 04:13AM JMP securities lowers Esperion Therapeutics Price Target to $4 (ESPR)
Jan 23, 2025 07:07AM JMP Securities Reiterates Market Outperform Rating on Esperion Therapeutics (ESPR)
Jan 16, 2025 10:28AM Esperion Therapeutics (ESPR): research & development expenses are expected to be in the range of $55 million to $65 million
Dec 18, 2024 07:01AM Esperion Therapeutics (ESPR) Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
Dec 18, 2024 04:26AM Goldman Sachs Reinstates Esperion Therapeutics (ESPR) at Neutral
Dec 17, 2024 06:32AM Cantor Fitzgerald Starts Esperion Therapeutics (ESPR) at Overweight
Dec 13, 2024 06:15AM Esperion Therapeutics (ESPR) Announces $210M Convertible Debt Financing
Dec 12, 2024 08:01AM Esperion Therapeutics (ESPR) Partners with Neopharm to Commercialize NEXLETOL and NEXLIZET in Israel
Dec 3, 2024 07:02AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)
View More Recent Stories View Older Stories